Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Apr;22(2):77-9.
doi: 10.3747/co.22.2579.

The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?

T Younis  1 , A Groom  1
Affiliations

The value-for-money of adjuvant aromatase inhibitors: time to put the debate to rest?

T Younis et al. Curr Oncol. 2015 Apr.
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Burstein HJ, Prestrud AA, Seidenfeld J, et al. on behalf of the American Society of Clinical Oncology American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor–positive breast cancer. J Clin Oncol. 2010;28:3784–96. doi: 10.1200/JCO.2009.26.3756. - DOI - PMC - PubMed
    1. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28:509–18. doi: 10.1200/JCO.2009.23.1274. - DOI - PubMed
    1. Jang S, Chae YK, Haddad T, Majhail NS. Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review. Breast Cancer Res Treat. 2010;121:273–9. doi: 10.1007/s10549-010-0870-7. - DOI - PubMed
    1. John–Baptiste AA, Wu W, Rochon P, Anderson GM, Bell CM. A systematic review and methodological evaluation of published cost-effectiveness analyses of aromatase inhibitors versus tamoxifen in early stage breast cancer. PLoS One. 2013;8:e62614. doi: 10.1371/journal.pone.0062614. - DOI - PMC - PubMed
    1. Rocchi A, Verma S. Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the atac completed-treatment analysis. Support Care Cancer. 2006;14:917–27. doi: 10.1007/s00520-006-0035-8. - DOI - PubMed

LinkOut - more resources